CureMetrix

San Diego, CA, USA All United States companies → — Founded 2014

Imaging AI Specialist Specialty-Focused AI

Cardiology Obstetrics & Gynecology Oncology Radiology

Cardiology AI OB/GYN AI Oncology AI Radiology & Imaging AI

Series C

Claim this company

Products

cmTriage

CureMetrix

Oncology AI

CureMetrix cmTriage is an FDA-cleared AI-based triage solution for mammography that enables radiologists to sort and prioritize their worklist based on suspicious cases, improving workflow efficiency and potentially accelerating breast cancer detection.

cmAngio®

CureMetrix

Cardiology AI

cmAngio® by CureMetrix is FDA-cleared AI software for detecting Breast Arterial Calcifications (BAC) on mammograms, providing insights into cardiovascular health and aiding early risk assessment.

Paid, out-of-pocket

See all 2 products →

About CureMetrix

CureMetrix is a healthcare AI company dedicated to improving disease detection and patient outcomes, particularly in women’s health. They develop FDA-cleared software that leverages artificial intelligence and deep learning for medical image analysis. Their primary focus is on mammography, providing radiologists with precision tools to enhance the accuracy of detecting and classifying anomalies such as breast arterial calcifications (BACs), masses, and calcifications. The company’s technology aims to integrate seamlessly into existing clinical workflows, offering data-driven insights to support radiologists in making informed decisions, ultimately improving diagnostic sensitivity and reducing false positives and unnecessary follow-up procedures.

Beyond breast cancer detection, CureMetrix’s vision extends to applying AI to improve outcomes in other medical fields, including heart and kidney diseases. Their products, such as cmAngio and cmTriage, are designed to optimize mammography workflows, detect and quantify BACs, and prioritize suspicious findings for immediate review. CureMetrix emphasizes that its algorithms are data-agnostic and have been trained and validated using a vast database of over 5 million images, ensuring high accuracy and reliability. The company holds ISO 13485:2016 certification for Quality Management Systems and has obtained FDA clearance for its cmAngio software.

Focus Areas

Artificial Intelligence Medical Imaging Mammography Breast Cancer Detection Breast Arterial Calcification Detection Cardiology Diagnostics & Imaging

Business Intelligence

Technology

Cloud-native, AI and deep learning techniques, algorithms trained on diverse databases of over 5 million images

What Physicians Need to Know

Breast Cancer Detection (Mammography)

CureMetrix offers AI-powered solutions like cmTriage® for workflow optimization and cmAssist® (in development) for cancer detection scoring. These tools aim to improve the accuracy and detection of anomalies in mammography, reduce reading time by up to 30%, and decrease false positives by as much as 63%. The AI highlights regions of interest and provides confidence scores, assisting radiologists in making better, faster decisions.

Breast Arterial Calcification (BAC) Detection & Cardiovascular Risk Assessment

CureMetrix specializes in cmAngio®, the first and only FDA-cleared AI software that detects, quantifies, and contextualizes Breast Arterial Calcifications (BAC) from routine screening mammograms. BAC, often an incidental finding, is a significant indicator of systemic vascular disease and an independent predictor of heart attack, heart failure, stroke, and all-cause mortality. cmAngio® turns a mammogram into a '2-for-1' exam, providing cardiovascular risk insights without additional imaging or cost.

Oncology

While primarily focused on early detection through mammography, CureMetrix's efforts in improving breast cancer detection directly contribute to oncology by enabling earlier diagnosis and potentially better treatment outcomes. Their AI solutions aim to help radiologists find cancers early to improve survival rates.

Key Differentiators

CureMetrix stands out with its FDA-cleared AI solutions, particularly cmAngio® as the first and only AI to detect, quantify, and contextualize BAC. Their technology reduces human error, decreases reading time, and significantly lowers false positives in mammography. The company emphasizes improving healthcare for women globally by integrating precision AI into existing workflows to detect critical conditions sooner.

Technology Stack

CureMetrix utilizes AI and machine learning-driven platforms for medical image analysis. Their solutions are cloud-based, PACS agnostic, HIPAA and DICOM compliant, and FHIR-enabled for interoperability. They process both Full Field Digital Mammography (FFDM) and Digital Breast Tomosynthesis (DBT) images from various systems like Hologic and GE. The company is also ISO 13485:2016 and MDSAP certified for medical device software development.

Physician Tip

For physicians, CureMetrix's AI solutions offer enhanced accuracy and efficiency in mammography interpretation. cmTriage® can optimize workflow by prioritizing suspicious cases, while cmAngio® provides crucial cardiovascular risk insights from existing mammograms, enabling a '2-for-1' screening. This allows for early identification of patients who may benefit from further cardiovascular evaluation without additional procedures or radiation. The AI tools are designed to integrate seamlessly into existing PACS systems, providing objective measurements and contextualization to support clinical decision-making and reduce variability in readings. Participating in ground truth studies with CureMetrix also offers radiologists an opportunity to contribute to cutting-edge AI development and earn compensation.

CureMetrix's solutions are designed for easy integration into existing radiology tools and clinical workflows. They are PACS agnostic and cloud-based, ensuring compatibility with various systems. The platforms are HIPAA and DICOM compliant, and FHIR-enabled for streamlined EHR integration and downstream interoperability, allowing for a 4-week implementation process. CureMetrix also partners with other AI imaging companies, such as Therapixel, to expand access and streamline integrations for a more holistic approach to women's health.

Products by CureMetrix

2 products in the directory

cmTriage

CureMetrix

Oncology AI

cmAngio®

CureMetrix

Cardiology AI

cmAngio® by CureMetrix is FDA-cleared AI software for detecting Breast Arterial Calcifications (BAC) on mammograms, providing insights into cardiovascular health and aiding early risk assessment.

Paid, out-of-pocket

What the Web Says

CureMetrix is a medical imaging AI company that develops FDA-cleared software to assist radiologists in interpreting screening mammograms, aiming to improve cancer detection and workflow efficiency. The company's solutions utilize deep learning to analyze breast images, identify suspicious regions, and provide quantitative scores to support clinical decision-making. Preliminary studies suggest their algorithm can reduce false-positive rates, potentially leading to fewer unnecessary follow-up procedures and reduced patient anxiety. While there is positive sentiment regarding their product's impact on cancer detection and workflow, there is limited information available on employer reviews across the requested platforms.

Overall: Mixed

Strengths

Improved sensitivity and specificity for detecting breast cancer with AI software.
Radiologists can read normal cases faster with AI assistance.
Potential to reduce false-positive rates, leading to fewer unnecessary procedures.
Aids in early detection and improves consistency, confidence, and quality of care in breast density assessment.
Cloud-based and on-premise solutions available.
Focus on advancing technology to improve disease detection and cancer survival rates globally.

Limitations

Limited public employee reviews available on platforms like Glassdoor, G2, and Capterra.
Comparably shows 0% positive employee reviews out of 0 reviews, indicating a lack of data rather than negative sentiment.
No specific product reviews found on G2 or Capterra for CureMetrix, though general healthcare software reviews mention upfront costs and transition challenges.
Reddit discussions about thermography (a different breast imaging method) show skepticism from radiologists, but no direct reviews of CureMetrix's AI mammography product.

Based on reviews from: Arbolus, SourceForge, Comparably, AuntMinnie, CureMetrix AI Blog

Last updated: 2026-10-19

Videos

News, demos, and interviews about CureMetrix.

Loading videos...

Videos load interactively. If none appear, search YouTube for CureMetrix →

View all on YouTube

Press & Coverage

EIN Presswire

FDA Clears CureMetrix's cmAngio 2.0, Introducing BAC Quantification and Age-Based Context

CureMetrix received FDA 510(k) clearance for cmAngio 2.0, an AI software that detects and quantifies breast arterial calcification on screening mammograms, adding quantitative measurement and age-based context.

2026-08

AuntMinnie

CureMetrix secures FDA clearance for cmAngio 2.0

CureMetrix has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for cmAngio 2.0, the latest version of its AI-based software for Breast Arterial Calcification (BAC) detection on screening mammograms.

2026-08

EIN Presswire

Suffolk Breast Imaging Redefines Routine Mammography with CureMetrix's cmAngio®

Suffolk Breast Imaging announced the enhancement of routine screening mammography with AI-powered Breast Arterial Calcification detection using CureMetrix's cmAngio.

2026-09

Imaging Technology News

CureMetrix Mammogram Software Expands FDA Clearance, Validated on GE, Hologic Platforms

CureMetrix expanded FDA clearance for cmAngio to include GE Healthcare, increasing access for more women to AI-powered BAC detection in mammography.

2025-04

Imaging Technology News

CureMetrix and Therapixel Partner to Integrate AI Mammography Technologies

CureMetrix announced a partnership with Therapixel to integrate CureMetrix's cmAngio and Therapixel's MammoScreen technologies, aiming to expand access to both AI-based mammography solutions.

2025-12

EIN Presswire

EvoNexus Company, CureMetrix, Partners with Volpara Health to Enhance AI-Driven Mammography Solutions for Breast Cancer Screening

CureMetrix announced an agreement with Volpara Health, a Lunit company, to make cmAngio available to thousands of providers through Volpara's platform.

2025-02

Signalbase

CureMetrix Secures $30 Million in Series C Funding for Advanced Medical Image Analysis Technology

CureMetrix successfully raised $30 million in Series C funding to advance its mission of enhancing disease detection and survival rates worldwide through AI-based medical imaging.

2024-09

EIN Presswire

Rezolut and CureMetrix Embark on AI Innovation Partnership

Rezolut, LLC and CureMetrix, Inc. launched a pilot program in the Greater New York City area to improve breast cancer detection in women receiving routine screening mammograms by pairing advanced technology with operational excellence.

2021-08

Frequently Asked Questions

What specific AI-powered solutions does CureMetrix offer for medical image analysis, particularly in breast cancer detection and cardiovascular risk assessment?

CureMetrix offers cmTriage, an AI-powered mammography solution designed to help radiologists prioritize and manage their reading workflow by flagging suspicious cases. They also provide cmAssist, which offers concurrent read and decision support for mammography, aiding in earlier and more accurate breast cancer detection. Additionally, CureMetrix's technology can detect and quantify Breast Arterial Calcification (BAC), which is increasingly recognized as a potential indicator for cardiovascular risk assessment.

How do CureMetrix's AI algorithms for mammography improve breast cancer detection rates and workflow efficiency for radiologists?

CureMetrix's AI algorithms, such as cmAssist, function as a concurrent read and decision support tool, providing a 'second pair of eyes' to help radiologists identify subtle abnormalities that might indicate breast cancer. This can lead to earlier detection and improved accuracy. cmTriage further enhances workflow efficiency by intelligently prioritizing cases that are more likely to contain actionable findings, allowing radiologists to manage their workload more effectively and focus on critical cases.

What is CureMetrix's approach to detecting Breast Arterial Calcification (BAC) and how can this information be integrated into a patient's cardiovascular risk assessment?

CureMetrix's AI technology can identify and quantify Breast Arterial Calcification (BAC) from standard mammograms. While not a direct diagnostic tool for cardiovascular disease, the presence and extent of BAC are increasingly being studied as potential indicators of a woman's cardiovascular risk. This information can be provided to the referring physician, who can then integrate it with other clinical data to make a more comprehensive cardiovascular risk assessment and guide further patient management.

What regulatory clearances and compliance standards (e.g., FDA, HIPAA) do CureMetrix's products hold, and how do they ensure data privacy and security?

CureMetrix products, including cmTriage and cmAssist, have received FDA clearance, demonstrating their safety and efficacy for clinical use in the United States. The company adheres to stringent data privacy and security protocols, complying with HIPAA regulations to protect sensitive patient health information. They employ robust encryption and access controls to ensure the confidentiality and integrity of all data processed through their AI platforms.

What is the typical pricing model for CureMetrix's AI solutions, and what kind of technical support and training does the company offer to healthcare providers?

CureMetrix typically offers flexible pricing models for its AI solutions, which can vary based on the size of the healthcare facility and the specific products implemented. They provide comprehensive technical support, including integration assistance, ongoing maintenance, and troubleshooting. CureMetrix also offers thorough training programs for radiologists, technologists, and IT staff to ensure seamless adoption and optimal utilization of their AI platforms within the clinical workflow.

Can CureMetrix's AI solutions be integrated with existing PACS and EMR systems, and what are the typical IT requirements for implementation?

Yes, CureMetrix's AI solutions are designed for seamless integration with existing Picture Archiving and Communication Systems (PACS) and Electronic Medical Record (EMR) systems commonly used in healthcare facilities. This ensures a smooth workflow and easy access to AI-generated insights within the radiologist's existing environment. Typical IT requirements for implementation are generally standard for medical imaging software, often involving network connectivity, server specifications, and adherence to security protocols, which CureMetrix's technical team assists with during the implementation process.

What is CureMetrix's long-term vision for AI in oncology and cardiovascular health, and what strategic partnerships do they have to advance their mission?

CureMetrix's long-term vision is to continue advancing the role of AI in early disease detection and risk assessment, particularly in oncology and cardiovascular health, to improve patient outcomes. They aim to expand their AI capabilities beyond mammography to other imaging modalities and disease areas. CureMetrix actively seeks strategic partnerships with leading academic institutions, research organizations, and other healthcare technology companies to further develop their AI algorithms, validate their clinical utility, and broaden the reach of their innovative solutions.